# Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients

> **NCT01018979** · PHASE2 · COMPLETED · sponsor: **GPCR Therapeutics, Inc.** · enrollment: 19 (actual)

## Conditions studied

- Multiple Myeloma
- Non-Hodgkin Lymphoma
- Hodgkin Disease

## Interventions

- **DRUG:** TG-0054 (2.24 mg/kg)
- **DRUG:** TG-0054 (3.14 mg/kg)

## Key facts

- **NCT ID:** NCT01018979
- **Lead sponsor:** GPCR Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2021-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01018979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01018979, "Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01018979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*